PSCA

City of Hope to Present New Research at the American Association of Cancer Research (AACR) Annual Meeting 2024, Highlighting Promising Data on Prostate, Colorectal and Pancreatic Cancer

Retrieved on: 
Tuesday, March 12, 2024
Research, Other Health, General Health, Pharmaceutical, Oncology, Biometrics, Hospitals, Genetics, Health Technology, Science, Biotechnology, Health, Other Science, Breast cancer, Syngenic, Convergent, Computational biology, Patient, Distinguishing, Beckman Research Institute, City, Tumor microenvironment, PSCA, Haematopoietic system, Memory, AACR, Lymphocyte, Treatment, Convergent Science, Neoplasm, Road, Systems biology, CRC, Division, Microbiome, Hematology, Pharmaceutical industry

To investigate why Hispanic/Latino colorectal cancer (CRC) patients in Los Angeles face mortality rates up to 20% higher than their Caucasian counterparts, City of Hope’s Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S.

Key Points: 
  • To investigate why Hispanic/Latino colorectal cancer (CRC) patients in Los Angeles face mortality rates up to 20% higher than their Caucasian counterparts, City of Hope’s Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S.
  • They found that the model was sensitive to microbiome modulation and that the use of patient-derived human fecal matter transfers can significantly impact PSCA-CAR T cell directed anti-tumor responses.
  • , will also chair the inaugural AACR event called From Cancer Discoveries to Patients on April 4 and 5.
  • The event brings together leaders in clinical research, biotech and the investment community as part of AACR’s commitment to expediting the advancement of lifesaving cancer discoveries.

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Completion of a Trial Protocol to Study its Self Assembling Vaccine to Target Prostate Stem Cell Antigen

Retrieved on: 
Monday, November 20, 2023
Antigen, PSCA, SAV, Therapy, Polysaccharide, Peptide, Protein, Epitope, Prostate cancer, Vaccine, Infection, Cancer, Survival, Massachusetts General Hospital, T cell, Neoplasm, Checkpoint, HPV, Dicarboxylic acid, Inflammation, Hospital, Checkpoint inhibitor, Voltron

NEW YORK, Nov. 20, 2023 /PRNewswire/ -- Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that it has finalized the protocol for a Dose-Ranging Efficacy Study of VTX-0P4, a protein-based cancer vaccine targeting Prostate Stem Cell Antigen (PSCA).

Key Points: 
  • NEW YORK, Nov. 20, 2023 /PRNewswire/ -- Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that it has finalized the protocol for a Dose-Ranging Efficacy Study of VTX-0P4, a protein-based cancer vaccine targeting Prostate Stem Cell Antigen (PSCA).
  • Voltron recently demonstrated immunogenicity against PSCA in a double blind pre-clinical trial conducted at the Vaccine and Immunotherapy Center at the Massachusetts General Hospital.
  • In that trial VTX-0P4 significantly augmented T-Cell responses when compared to controls against this important tumor target while, once again, exhibiting a very clean safety profile.
  • "We are excited to initiate Voltron's PSCA pre-clinical efficacy trial," said James Ahern, Managing Partner of Laidlaw & Company and co-founder of Lucius Partners.

PercAssist Announces First Patient Treated in EUREKA Study of PSCA System for Hemodynamic Support in Chronic Heart Failure

Retrieved on: 
Thursday, September 28, 2023
Technology, Medical Devices, Clinical Trials, Cardiology, Software, Hardware, Health, General Health, Data Management, Acute decompensated heart failure, Heart failure, Cardiogenic shock, Heart, Pivotal trial, Cardiac output, Trial of the century, PSCA, Patient, IDE, EUREKA, FESC, Medical device, Pharmaceutical industry

PercAssist, Inc ., a medical device company developing innovative technology for a minimally invasive, extravascular platform to provide hemodynamic support for chronic heart failure patients, today announced the successful completion of its first patient in the EUREKA First-in-Human clinical study.

Key Points: 
  • PercAssist, Inc ., a medical device company developing innovative technology for a minimally invasive, extravascular platform to provide hemodynamic support for chronic heart failure patients, today announced the successful completion of its first patient in the EUREKA First-in-Human clinical study.
  • The PSCA System was successfully deployed and provided hemodynamic stability immediately following implantation and throughout the implant period.
  • “We are extremely excited to lead the First-in-Human clinical investigation of the PercAssist PSCA System for chronic heart failure patients requiring hemodynamic support,” said Professor Neuzil.
  • This extravascular ventricular assist technology has tremendous potential for providing hemodynamic support for heart failure patients without the need for anticoagulation therapy.

University of Pittsburgh, Duquesne University Win Prestigious Participant Education Awards

Retrieved on: 
Tuesday, June 6, 2023
Duquesne University, University, Education, Pittsburgh, Consultant, University of Pittsburgh, PSCA, TIAA, Retirement, Investment, Duquesne, Conference, Life insurance

The Plan Sponsor Council of America , a retirement industry group, presents the Signature Awards annually in various categories for exemplary plan education with an emphasis on creatively targeting education to an employer's workforce, resulting in tangible positive outcomes.

Key Points: 
  • The Plan Sponsor Council of America , a retirement industry group, presents the Signature Awards annually in various categories for exemplary plan education with an emphasis on creatively targeting education to an employer's workforce, resulting in tangible positive outcomes.
  • Pitt won first place in the "Plan Changes" category, and Duquesne won second place in the "Conversion" category.
  • A panel of 23 business leaders evaluated and selected the winners of the 2023 Signature Awards from 66 entries in eight key categories.
  • Duquesne chose to streamline administration and provide easier retirement planning, enhanced services and education for employees, resulting in consolidating recordkeepers to a single-service provider.

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

Retrieved on: 
Thursday, May 18, 2023
Waldenström macroglobulinemia, Partnership, City of Hope, Mayo Clinic, Employment, Birmingham School of Law, Malignancy, University, GBM, CD20, Fred Hutchinson Cancer Research Center, Neoplasm, Biotechnology, Lead, University of Massachusetts Chan Medical School, Translation, Sale, WM, Security, CAR, PSCA, CDMO, Hematological Cancer Research Investment and Education Act, City, Waldenström, Acquisition, CGMP, Patient, Cancer, XSCID, Birmingham, Ecosystem, Nationwide, Mustang, IND, DSM-IV codes, Leiden University, Vaccine, Bank, Pharmaceutical industry, Fine chemical, Greater Boston

WORCESTER, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced a strategic update, including anticipated milestones for 2023. Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology. Additionally, Mustang announced a partnership with uBriGene (Boston) Biosciences Inc. (“uBriGene”), the U.S. subsidiary of uBriGene Group, a leading cell and gene therapy contract development and manufacturing organization (“CDMO”), which includes the sale of the Company’s development, manufacturing and analytical testing facility in Worcester, Massachusetts to uBriGene.

Key Points: 
  • Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology.
  • Additionally, Mustang announced a partnership with uBriGene (Boston) Biosciences Inc. (“uBriGene”), the U.S. subsidiary of uBriGene Group, a leading cell and gene therapy contract development and manufacturing organization (“CDMO”), which includes the sale of the Company’s development, manufacturing and analytical testing facility in Worcester, Massachusetts to uBriGene.
  • Subject to closing, the parties will enter into a manufacturing supply agreement, under which uBriGene will manufacture Mustang’s lead product candidates, including continuing to support MB-106 manufacturing for the ongoing multi-center Phase 1/2 trial.
  • I want to thank our manufacturing team for their dedication in building and growing our Worcester facility since it opened in 2018.

City of Hope to present latest data on cellular therapy, potential new medicines and natural products at the American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on: 
Thursday, March 16, 2023
Cancer, RIN, Tumor microenvironment, Liver disease, LOS, Cell death, Behavioral Risk Factor Surveillance System, Eye, Asahi, City, CD8, PSCA, Polyphenol, Cell, Colorectal cancer, Prostate cancer, CAR, PDAC, CD4, Protein, Ipilimumab, Patient, CRC, COVID-19, Berberine, Bias, MSS, Clinical trial, Medicine, Behavioral risk, Plant, Diabetes, Nivolumab, Nursing, Medical imaging, Hope

LOS ANGELES, March 16, 2023 /PRNewswire/ -- Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, will present a number of new findings at this year's American Association for Cancer Research Annual Meeting, which will take place April 14 to 19.

Key Points: 
  • For patients with metastatic castration resistant prostate cancer (mCRPC), durable treatment options are currently limited.
  • Lopez and the team have established dual-targeted CAR T cell approaches that have potential to reach clinical trial for patients with mCRPC.
  • To do this, City of Hope partnered with four federally qualified health centers as well as local organizations to help improve CRC screenings.
  • Those who experienced a clinical benefit from RIN had a more robust immune activation of the tumor microenvironment after one cycle.

Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium

Retrieved on: 
Thursday, February 16, 2023
CD40, Prostate cancer, IL-6, PSCA, HLH, Patient, Metastasis, Cancer, IMC, RECIST, Sepsis, Aplastic anemia, MYD88, Serum, Hemophagocytic lymphohistiocytosis, CRS, Society, ASCO, Medical imaging, Pharmaceutical industry, Vaccine

HOUSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today will present early Phase 1 results for BPX-601 at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco and virtually. The poster titled “Early Results from a Phase 1, Multicenter Trial of PSCA-Specific GoCAR T® Cells (BPX-601) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)” presents initial data from the first two cohorts (n=8) treated with BPX-601. These interim results demonstrated preliminary efficacy of BPX-601 PSCA-directed GoCAR-T cells in combination with rimiducid in heavily pre-treated patients.

Key Points: 
  • The poster titled “Early Results from a Phase 1, Multicenter Trial of PSCA-Specific GoCAR T® Cells (BPX-601) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)” presents initial data from the first two cohorts (n=8) treated with BPX-601.
  • These interim results demonstrated preliminary efficacy of BPX-601 PSCA-directed GoCAR-T cells in combination with rimiducid in heavily pre-treated patients.
  • “We believe these encouraging initial clinical results in mCRPC support the potential of BPX-601 and the GoCAR-T® platform,” stated Rick Fair, President and Chief Executive Officer, Bellicum Pharmaceuticals.
  • GoCAR-T cells are designed to function optimally with repeat dosing of rimiducid to induce the co-activation molecules MyD88 and CD40.

Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer

Retrieved on: 
Tuesday, December 20, 2022
Biotechnology, Hospitals, Pharmaceutical, Health, PSMA, Eli Lilly and Company, PSCA, Ropes & Gray, Patient, DRS, Social media, Penn, Cooley, Lymphatic system, CAR, University, Invention, Partnership, Cell engineering, EPS, IPR, American Cancer Society, Risk, Centerview Partners, MD, Clinical trial, HIV, ARLA, Non-executive director, Doctor of Philosophy, Gilead Sciences, Hart–Scott–Rodino Antitrust Improvements Act, Research, Cancer, Acquisition, Pharmaceutical industry, Medical imaging, Security (finance), Chewing, Immunotherapy, Medicine, Twitter

Kite, a Gilead Company (Nasdaq: GILD), and Tmunity Therapeutics (Tmunity), today announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.

Key Points: 
  • Kite, a Gilead Company (Nasdaq: GILD), and Tmunity Therapeutics (Tmunity), today announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.
  • As part of Kite’s acquisition, the Tmunity founders will become senior scientific advisors for Kite.
  • Kite will acquire all outstanding shares of Tmunity other than those already owned by Kite.
  • As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company.

Are HSAs starting to Resemble 401(k)s?

Retrieved on: 
Wednesday, October 26, 2022
HDHP, Growth, Education, Research, Webster Bank, HSA, Goal, HSAS, HSA Bank, ARA, FDIC, PSCA, Benchmarking, Retirement, Health insurance, Bank

MILWAUKEE, Oct. 26, 2022 /PRNewswire/ -- Health savings accounts (HSAs) may still be used more as spending accounts than savings accounts, but the Plan Sponsor Council of America's (PSCA) 2022 Health Savings Account Survey, sponsored by HSA Bank, finds signs that retirement plans are starting to influence HSA program designs.

Key Points: 
  • Automatically opening HSAs and enrolling employees dramatically increases the savings rate.
  • Moreover, nearly six-in-ten (57.2 percent) allow rollovers from HSAs for newly hired workers, and nearly two-thirds (61.9 percent) educate and encourage rollovers from other HSAs moves that support the growth of these savings accounts.
  • "HSAs can be an important part of a holistic retirement savings approach to address these concerns."
  • Yet, most employers only provide education about HSAs during open enrollment (61%) or when onboarding employees.

Amid economic uncertainty, nonprofits enhancing 403(b) retirement plans for employees

Retrieved on: 
Thursday, September 29, 2022
Banking, Accounting, Professional Services, Finance, Workforce, COVID-19, Principal, Organization, Principal Financial Group, Retirement, Inc., Habit, SIPC, No, Bloomberg, Nasdaq, Solution, National Equity Fund, Inc., PSCA, Research, Broker-dealer, PFG, Education, Income, Health insurance, Management, Animal, Financial adviser, Renewable energy, Security (finance)

It found more eligible employees utilized retirement plans in 2021 (83.4%) than in 2020 (82.6%).

Key Points: 
  • It found more eligible employees utilized retirement plans in 2021 (83.4%) than in 2020 (82.6%).
  • An average of 79.4% of eligible employees made contributions to their plans in 2021, an increase from 77.2% in 2020.
  • This bodes well for the resiliency of retirement plans, and for non-profit organizations and workers as we again face economic uncertainty amid market volatility and inflation.
  • The percentage of plans providing immediate eligibility rose for both matching and non-matching contributions by 7% and 20%, respectively.